Indications
Targeting multiple major indications, including metastatic HR+/HER2- breast cancer, triple-negative breast cancer；
Non-small cell lung cancer, as well as various urological and gynecological tumors.
Development Progress
Entered Phase III clinical trials in China.
Indications
B-cell malignancies, autoimmune diseases.
Development Progress
Phase I dose-escalation trial in lymphoma completed;
Well-tolerated in lymphoma patients; efficacy demonstrated in relapse and resistant lymphoma patients.
ADC Drugs
mAb Drugs
